CSL (CMXHF) Receives a Buy from UBS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2025
0mins
Source: Business Insider
Analyst Ratings: UBS analyst Laura Sutcliffe has maintained a Buy rating on CSL with a price target of A$310.00, while Morgan Stanley also supports a Buy rating with a target of A$313.00. CSL's shares closed at $146.35 and have a consensus rating of Strong Buy.
Insider Activity and Market Performance: CSL has a market cap of $73.79B and a positive sentiment from corporate insiders, indicating increased insider buying activity. The stock has an average return of 5.0% from Sutcliffe, who covers the Healthcare sector.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
